|
|
|
|
|
Delaware
|
|
001-16043
|
|
13-3304550
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Exhibit
Number
|
Description
|
3.1
|
Amended
and Restated By-laws of Synvista Therapeutics, Inc.
|
10.1
|
Consulting
Agreement by and between the Company and Dr. MacNab dated January
1,
2008.
|
SYNVISTA THERAPEUTICS, INC. | ||
|
|
|
Dated: December 7, 2007 | By: | /s/ Noah Berkowitz |
Noah Berkowitz, M.D., Ph.D. |
||
President and Chief Executive Officer |
Exhibit
Number
|
Description
|
3.1
|
Amended
and Restated By-laws of Synvista Therapeutics, Inc.
|
10.1
|
Consulting
Agreement by and between the Company and Dr. MacNab dated January
1,
2008.
|